WO2024105689A1 - Nouvelle composition ophtalmique - Google Patents

Nouvelle composition ophtalmique Download PDF

Info

Publication number
WO2024105689A1
WO2024105689A1 PCT/IN2023/051033 IN2023051033W WO2024105689A1 WO 2024105689 A1 WO2024105689 A1 WO 2024105689A1 IN 2023051033 W IN2023051033 W IN 2023051033W WO 2024105689 A1 WO2024105689 A1 WO 2024105689A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
plazomicin
pharmaceutically acceptable
present
agent
Prior art date
Application number
PCT/IN2023/051033
Other languages
English (en)
Inventor
Arunprasath Kaliaperumal
Preeti Prashant RAUT
Trupti CHITRE
Vinayak MARATHE
Rahul NARKHEDE
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of WO2024105689A1 publication Critical patent/WO2024105689A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • Infection can be mono or poly-microbial and is associated with many factors including contact lenses, trauma, surgery, age, dry eyes, chronic nasolacrimal duct obstruction and previous ocular infections.
  • Bacteria are generally associated with many types of ocular infections such as conjunctivitis, keratitis, endophthalmitis, blepharitis, orbital cellulitis and dacryocystitis manifestations.
  • the most common bacteria involved in ocular infections are Staphylococcus aureus (S. aureus), Coagulase-negative staphylococci (CoNS), Streptococcus pneumoniae, Corynebacterium spp., Bacillus spp., Nocardia, Pseudomonas aeruginosa, Haemophilus influenzae and Enterobacteriaceae .
  • S. aureus Staphylococcus aureus
  • CoNS Coagulase-negative staphylococci
  • Streptococcus pneumoniae Corynebacterium spp.
  • Bacillus spp. Nocardia, Pseudomonas aeruginosa, Haemophilus influenzae and
  • aureus and CoNS strains are very important for their high prevalence of infection, while S. aureus is among the most common cause of blepharitis, conjunctivitis, dacryocystitis, keratitis and endophthalmitis.
  • Aminoglycoside antibiotics have a broad antibacterial spectrum against gram-positive and gram-negative bacteria, and it is said that their action mechanism is based on inhibition of bacterial protein synthesis. Aminoglycoside antibiotics show long- lasting inhibitory effect on the inhibition of bacterial growth, as they exhibit postantibiotic effect (PAE) on the inhibition of bacterial growth even after the blood concentration of the aminoglycoside antibiotics is decreased to a concentration of MIC (minimum inhibitory concentration) or less.
  • PAE postantibiotic effect
  • Plazomicin is an aminoglycoside that was engineered to overcome aminoglycosidemodifying enzymes (AMEs), the most common aminoglycoside resistance mechanism in the Enterobacteriaceae .
  • AMEs aminoglycosidemodifying enzymes
  • it is an objective of the present invention to provide an ophthalmic composition comprising plazomicin or its pharmaceutically acceptable salts thereof.
  • An object of the present invention is to provide an ophthalmic pharmaceutical composition comprising plazomicin or its pharmaceutically acceptable salts thereof.
  • Another objective of this invention is to develop an ophthalmic composition comprising plazomicin or its pharmaceutically acceptable salts thereof for the treatment of external infections of the eye and its adnexa.
  • the external infections of the eye may be caused by susceptible bacteria like S.aureus ( MSSA/MRSA), Coagulase negative S.aureus, S.epidermidis, Klebsiella and Proteus.
  • an objective of this invention is to develop an ophthalmic composition
  • ophthalmic composition comprising plazomicin or its pharmaceutically acceptable salts thereof for the treatment of bacterial keratitis.
  • the composition may optionally contain a second antibacterial such as cephalosporin.
  • the present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic and a process to prepare the same. More particularly, the present invention relates to a pharmaceutical composition comprising aminoglycoside antibiotics such as plazomicin or its pharmaceutically acceptable salts thereof for the treatment of ocular infections.
  • the composition of the present invention comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof. In another embodiment, the composition of the present invention comprises plazomicin sulfate.
  • composition of the present invention further comprises atleast one excipient selected from buffering agent, tonicity adjusting agent, viscosity modifying agent, preservative, chelating agent and pH adjusting agent.
  • composition of the present invention further comprises about 0.01% w/v to about 1.5% w/v buffering agent. In another embodiment, the composition of the present invention further comprises about 0.01% w/v to about 5% w/v buffering agent.
  • the composition of the present invention further comprises about 0.01% w/v to about 1.5% w/v tonicity adjusting agent. In another embodiment, the composition of the present invention further comprises about 0.1% w/v to about 6% w/v tonicity adjusting agent.
  • composition of the present invention further comprises about 0.01% w/v to about 3% w/v preservative. In an embodiment, the composition of the present invention further comprises about 0. 00010% w/v to about 1% w/v preservative.
  • the composition of the present invention comprises about 0.01% w/v to about 5% w/v viscosity modifying agent.
  • the composition of the present invention comprises about 0.001% w/v to about 1% w/v chelating agent.
  • the composition of the present invention further comprises a pH adjusting agent.
  • the composition of the present invention is an aqueous composition.
  • composition of the present invention comprises plazomicin or its pharmaceutically acceptable salt in a solubilized form.
  • the present invention relates to an ophthalmic composition for use in ocular infections.
  • the inventors of this invention have developed an ophthalmic pharmaceutical composition comprising plazomicin or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
  • Plazomicin is chemically known as (2"R,3"R,4"R,5"R)-2"-[(lS,2S,3R,4S,6R)-4- amino-6-[(2"'S)-4"'-amino-2"'-hydroxybutanamido)amino]-3-[(2'S,3'R)-3'-amino-6'- ((2- hydroxy ethylamino) methyl)-3',4'-dihydro-2H-pyran-2'-yloxy]-2- hydroxycyclohexyloxy]-5"-methyl-4"-(methylamino)tetrahydro-2H-pyran-3",5"-diol.
  • Suitable salts of plazomicin include, but are not limited to sulfate, hydrochloric, hydrobromic, hydroiodic, methylsulfonic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic pyruvic, malonic, succinic, maleic, fumaric, maleic, tartaric, citric, benzoic, carbonic cinnamic, mandelic, methanesulfonic, ethanesulfonic, benezenesulfonic, hydroxyethanesulfonic, p-toluene sulfonic, cyclohexanesulfamic, salicyclic, p- aminosalicylic, 2-phenoxybenzoic, and 2-acetoxy benzoic acid.
  • sulfate hydrochloric, hydrobromic, hydroiodic, methylsulfonic, perchloric, sulfuric, nitric, phospho
  • Plazomicin has similar activity to gentamicin (and greater activity than amikacin) against MRS A, MS SA. Plazomicin has potent activity against species of Staphylococcus. Against Gram-negative enteric bacteria, plazomicin demonstrates more potent in vitro activity than amikacin, gentamicin and tobramycin.
  • the inventors of the present invention have intensively studied on the above problems, resulting in finding that an ophthlamic composition containing plazomicin or its pharmaceutically acceptable salts thereof are able to treat the ocular infection, especially the ones where there is a development of bacterial resistance.
  • one aspect of the invention is to formulate an ophthalmic pharmaceutical composition
  • an ophthalmic pharmaceutical composition comprising plazomicin or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
  • compositions of the present invention are typically administered to the affected ophthalmic tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day.
  • the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic tissues during surgical procedures.
  • the pharmaceutical ophthalmic compositions may comprise one or more pharmaceutically acceptable excipients suitable for formulating the same which include, but are not limited to, suspending agents, pH adjusters, tonicity adjusting agents, emulsifiers or dispersing agents, surfactants, solubilizers, buffering agents, preservatives, chelating agents, wetting agents, viscosity modifying agents, antioxidants, gelling agents, stabilizing agents and mixtures thereof.
  • pharmaceutically acceptable excipients suitable for formulating the same which include, but are not limited to, suspending agents, pH adjusters, tonicity adjusting agents, emulsifiers or dispersing agents, surfactants, solubilizers, buffering agents, preservatives, chelating agents, wetting agents, viscosity modifying agents, antioxidants, gelling agents, stabilizing agents and mixtures thereof.
  • Ophthalmic pharmaceutical products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include but are not limited to quaternary ammonium derivatives, benzalkonium chloride, benzylammonium chloride, cetylmethyl ammonium bromide, stabilized oxychloride complex, quaternium chloride, sodium perborate, benzododecinium bromide, zinc chloride, cetylpyridinium chloride, benzethonium chloride, chlorbutanol; chlorhexidine gluconate, chlorhexidine acetate, organomercury compounds (Thimerosal, phenylmercury acetate, phenylmercury nitrate), methyl and propyl p-hydroxy-benzoates, betaphenylethyl alcohol, benzyl alcohol, phenylethyl alcohol, phenoxyethanol, stabilized oxychloro complex (SOC), sofzia,
  • the composition of the present invention comprises preservatives in an amount of about 0.01% w/v to about 3.00% w/v. In another embodiment, the composition of the present invention comprises preservatives in an amount of about 0.00010% w/v to about 1.00% w/v. In a preferred embodiment, the composition of the present invention comprises about 0.02% w/v benzalkonium chloride.
  • the ophthalmic pharmaceutical composition of the present invention may optionally comprise one or more suspending agents.
  • Suitable suspending agents can be selected from but are not limited to water soluble/water-swellable polymers such as cellulosic polymers i.e. methyl cellulose, hydroxyl propyl methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, carboxy methyl cellulose, polyvinyl pyrrolidine, polyvinyl alcohol, carbopol, carbophil and one or more water-insoluble polymers such as cross-linked carboxyl-containing polymers, ethyl cellulose, and mixtures thereof.
  • water soluble/water-swellable polymers such as cellulosic polymers i.e. methyl cellulose, hydroxyl propyl methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, carboxy methyl cellulose, polyvinyl pyrrolidine, polyvinyl alcohol, carbopol, carbophil and one or more
  • suspending agents which may be used include, but are not limited to, acacia, agar, alginic acid, sodium alginate, bentonite, carrageenan, gelatin, tragacanth, xanthan gum, and derivatives thereof. Such agents can be used in the range of 0.005% to 1.5%w/v or as deemed fit for the composition.
  • composition may further comprise sterile water for injection as vehicle.
  • sterile water for injection as vehicle.
  • Other aqueous and non-aqueous vehicles may be used as a vehicle for the present ophthalmic composition.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v preservative, about 0.01% w/v to about 1.50% w/v of tonicity adjusting agent, about 0.01% w/v to about 1.50% w/v of buffering agent, about 0.01% w/v to about 1% w/v of viscosity adjusting agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v benzalkonium chloride, about 0.01% w/v to about 1.50% w/v sodium chloride, about 0.01% w/v to about 1.50% w/v boric acid, about 0.01% w/v to about 1% w/v hydroxy propyl guar gum and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.00010% w/v to about 1% w/v preservative, about 0.01% w/v to about 1.50% w/v of tonicity adjusting agent, about 0.01% w/v to about 1% w/v of buffering agent, about 0.01% w/v to about 5% w/v of viscosity adjusting agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.00010% w/v to about 1% w/v stabilized oxychloride complex, about 0.01% w/v to about 1.50% w/v sodium chloride, about 0.01% w/v to about 1% w/v citric acid and disodium citrate, about 0.01% w/v to about 5% w/v polyvinyl alcohol and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v preservative, about 0.01% w/v to about 1.50% w/v of tonicity adjusting agent, about 0.01% w/v to about 1% w/v of buffering agent, about 0.01% w/v to about 5% w/v of viscosity adjusting agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v quaternium chloride, about 0.01% w/v to about 1.50% w/v sodium chloride, about 0.01% w/v to about 1% w/v citric acid and disodium citrate, about 0.01% w/v to about 5% w/v polyvinyl alcohol and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1% w/v sodium perborate, about 0.01% w/v to about 1.50% w/v sodium chloride, about 0.01% w/v to about 1% w/v citric acid and disodium citrate, about 0.01% w/v to about 5% w/v polyvinyl alcohol and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v preservative, about 0.01% w/v to about 1.50% w/v of tonicity adjusting agent, about 0.01% w/v to about 1% w/v of buffering agent, about 0.01% w/v to about 5% w/v of viscosity adjusting agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 3% w/v benzododecinium bromide, about 0.01% w/v to about 1.50% w/v sodium chloride, about 0.01% w/v to about 1% w/v citric acid and disodium citrate, about 0.01% w/v to about 5% w/v polyvinyl alcohol and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.0010% w/v to about 0.1% w/v preservative, about 0.01% w/v to about 4% w/v of tonicity adjusting agent, about 0.01% w/v to about 1.5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.0010% w/v to about 0.1% w/v preservative, about 0.01% w/v to about 10% w/v of tonicity adjusting agent, about 0.01% w/v to about 1.5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.0010% w/v to about 0.1% w/v zinc chloride, about 0.01% w/v to about 2% w/v of propylene glycol, about 0.1% w/v to about 6% w/v mannitol, about 0.01% w/v to about 1.5% w/v of boric acid and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.1% w/v to about 6% w/v of tonicity adjusting agent, about 0.01% w/v to about 2.5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.1% w/v to about 6% w/v of mannitol, about 0.01% w/v to about 2.5% w/v of dibasic sodium phosphate and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of tonicity adjusting agent, about 0.01% w/v to about 2.5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of sodium chloride, about 0.01% w/v to about 2.5% w/v of dibasic sodium phosphate and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.1% w/v to about 6% w/v of tonicity adjusting agent, about 0.01% w/v to about 5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.1% w/v to about 6% w/v of mannitol, about 0.01% w/v to about 2.5% w/v of dibasic sodium phosphate, about 0.01% w/v to about 2.5% w/v of monobasic sodium phosphate and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of tonicity adjusting agent, about 0.01% w/v to about 5% w/v of buffering agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of sodium chloride, about 0.01% w/v to about 2.5% w/v of dibasic sodium phosphate, about 0.01% w/v to about 2.5% w/v of monobasic sodium phosphate and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of tonicity adjusting agent, about 0.01% w/v to about 5% w/v of buffering agent, about 0.01% w/v to about 3% w/v of preservative, about 0.001% w/v to about 1 % w/v of chelating agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.73% w/v of tonicity adjusting agent, about 0.3% w/v of buffering agent, about 0.02% w/v of preservative, about 0.1% w/v of chelating agent and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.01% w/v to about 1.5% w/v of sodium chloride, about 0.01% w/v to about 5% w/v of boric acid, about 0.01% w/v to about 3% w/v of benzalkonium chloride, about 0.001% w/v to about 1 % w/v of EDTA and water.
  • the ophthalmic composition comprises about 0.01% w/v to about 1.00% w/v plazomicin or its pharmaceutically acceptable salt thereof, about 0.73% w/v of sodium chloride, about 0.3% w/v of boric acid, about 0.02% w/v of benzalkonium chloride, about 0.1% w/v of EDTA and water.
  • the present invention relates to an ophthalmic composition for use in ocular infections.
  • the invention also relates to a process of preparing ophthalmic pharmaceutical composition- which comprises (i) autoclaving a slurry comprising the active ingredients and optionally other excipients; (ii) preparing a solution comprising other pharmaceutically acceptable excipients and autoclaving the same; (iii) aseptically adding the drug slurry to the excipient solution and (iv) finally making up the volume with vehicle.
  • the invention also relates to a process of preparing ophthalmic pharmaceutical composition which comprises (i) milling and autoclaving a slurry comprising the active ingredient, surfactant and suspending agent; (ii) preparing a solution comprising other pharmaceutically acceptable excipients and autoclaving the same; (iii) aseptically adding the preservative to the excipient solution; (iv) aseptically adding the drug slurry to the excipient solution and (v) finally making up the volume with vehicle.
  • the invention also relates to a process of preparing ophthalmic pharmaceutical composition which comprises (i) milling and autoclaving a slurry comprising the active ingredient, surfactant and suspending agent; (ii) preparing a solution comprising other pharmaceutically acceptable excipients, and preservative and autoclaving the same; (iii) aseptically adding the drug slurry to the excipient and preservative solution and (iv) finally making up the volume with vehicle.
  • the present invention also provides a method for the treatment and/or prevention of ophthalmic infections, which method comprises the administration of a therapeutically effective amount of a pharmaceutical composition according to the present invention.
  • composition of the present invention may be used topically in the treatment of ocular infections associated with inflammation such as conjunctivitis, dacryocystitis, hordeolum, keratitis, blepharitis and corneal ulcers thereof.
  • the composition of the present invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection.
  • step 4 Adjust pH of solution of step 4 with sodium hydroxide/ hydrochloric acid to 6.5 to 7.
  • a 96 well round bottomed plate was used for the Microbroth dilution assay.
  • the plate was incubated for 18-24 hours to read the Minimum Inhibitory Concentration (MIC).
  • MIC Minimum Inhibitory Concentration
  • MSSA Methicillin susceptible Staphylococcus aureus
  • MRSA Methicillin resistant Staphylococcus aureus
  • Plazomicin was active against MSSA isolates and 67.3% were susceptible (MIC50/90, 2/8 mcg/mL). Further 60% of MRSA isolates were susceptible (MIC50/90, 2/8 mcg/mL). Plazomicin showed activity for 50% of Pseudomonas spp. (MIC50/90, 4/16 mcg/mL). Majority of the Staphylococcus spp. (90.1%) were inhibited by plazomicin at ⁇ 8 mcg/mL, while 73.5% were inhibited at ⁇ 4 mcg/mL and 46% were inhibited at ⁇ 2 mcg/mL. Plazomicin showed 100% activity for S. epidermidis, S.
  • a buffering agent includes a single buffering agent as well as two or more different buffering agents; reference to a “solvent” refers to a single cosolvent or to combinations of two or more solvents, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle composition pharmaceutique appropriée pour une utilisation ophtalmique comprenant un antibiotique tel que la plazomicine ou ses sels pharmaceutiquement acceptables et un procédé de préparation de celle-ci pour une utilisation dans le traitement d'infections oculaires.
PCT/IN2023/051033 2022-11-14 2023-11-08 Nouvelle composition ophtalmique WO2024105689A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221065056 2022-11-14
IN202221065056 2022-11-14

Publications (1)

Publication Number Publication Date
WO2024105689A1 true WO2024105689A1 (fr) 2024-05-23

Family

ID=91083899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2023/051033 WO2024105689A1 (fr) 2022-11-14 2023-11-08 Nouvelle composition ophtalmique

Country Status (1)

Country Link
WO (1) WO2024105689A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358141A (zh) * 2013-05-01 2016-02-24 尼奥酷里私人有限公司 治疗细菌感染的方法
TWI665218B (zh) * 2013-05-22 2019-07-11 新製藥授權控股公司 多黏菌素化合物、包含其之醫藥組成物及其用途
EP3675838A1 (fr) * 2017-08-29 2020-07-08 Puretecch LYT, Inc. Promédicaments lipidiques orientant vers le système lymphatique
WO2022031830A1 (fr) * 2020-08-04 2022-02-10 Harrow Ip Llc Compositions antibactériennes et leurs procédés de fabrication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358141A (zh) * 2013-05-01 2016-02-24 尼奥酷里私人有限公司 治疗细菌感染的方法
TWI665218B (zh) * 2013-05-22 2019-07-11 新製藥授權控股公司 多黏菌素化合物、包含其之醫藥組成物及其用途
EP3675838A1 (fr) * 2017-08-29 2020-07-08 Puretecch LYT, Inc. Promédicaments lipidiques orientant vers le système lymphatique
WO2022031830A1 (fr) * 2020-08-04 2022-02-10 Harrow Ip Llc Compositions antibactériennes et leurs procédés de fabrication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALAN R. NOEL ET AL.: "Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 54, no. 5, 1 November 2019 (2019-11-01), pages 626 - 632, XP085889649, DOI: 10.1016/j.ijantimicag. 2019.07.00 1 *

Similar Documents

Publication Publication Date Title
JP6527341B2 (ja) ポビドンヨード、眼科用組成物のための新規代替保存剤
CA2753964C (fr) Compositions otiques utilisables dans le cadre du traitement d'infections de l'oreille interne et de l'oreille externe chez les mammiferes
CN110869023B (zh) 原位凝胶形成药物组合物及其在鼻窦疾病中的应用
EP3157507B1 (fr) Composition ophtalmique pour le traitement d'une infection oculaire
US6699492B2 (en) Quinolone carboxylic acid compositions and related methods of treatment
AU2002322002A1 (en) Quinolone carboxylic acid compositions and related methods of treatment
WO2024105689A1 (fr) Nouvelle composition ophtalmique
US20230338540A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
US20150133409A1 (en) Topical ophthalmic, otic, and nasal compositions of ciprofloxacin
AU2019268200B2 (en) Povidone iodine, a novel alternative preservative for ophthalmic compositions
WO2020141482A1 (fr) Compositions pharmaceutiques comprenant de la mupirocine
WO2022253970A1 (fr) Composition topique ophtalmique de ciprofloxacine pour le traitement d'une maladie oculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23891041

Country of ref document: EP

Kind code of ref document: A1